NASDAQ:AXDX

Accelerate Diagnostics Stock Forecast, Price & News

$8.63

-0.36 (-4.00 %)

(As of 06/16/2021 10:33 AM ET)

Add

Compare

Today's Range

$8.62

▼

$9.01

50-Day Range

$6.81

▼

$9.08

52-Week Range

$6.59

▼

$19.11

Volume1,407 shs

Average Volume414,706 shs

Market Capitalization$526.81 million

P/E RatioN/A

Dividend YieldN/A

Beta1.94

30 days | 90 days | 365 days | Advanced Chart

Receive AXDX News and Ratings via Email

Sign-up to receive the latest news and ratings for Accelerate Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Expected to Post Quarterly Sales of $3.19 Million
June 11, 2021 | americanbankingnews.com

-$0.35 Earnings Per Share Expected for Accelerate Diagnostics, Inc. (NASDAQ:AXDX) This Quarter
June 9, 2021 | americanbankingnews.com

Olink Holding AB (publ) (NASDAQ:OLK) versus Accelerate Diagnostics (NASDAQ:AXDX) Financial Analysis
May 28, 2021 | americanbankingnews.com

Analysts Expect Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Will Post Quarterly Sales of $3.39 Million
May 23, 2021 | americanbankingnews.com

Accelerate Diagnostics to Participate in William Blair 41st Annual Growth Stock Conference on June 3, 2021
May 19, 2021 | finance.yahoo.com

How Many Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Shares Did Insiders Buy, In The Last Year?
May 17, 2021 | nasdaq.com

Do Institutions Own Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Shares?
May 17, 2021 | finance.yahoo.com

Accelerate Diagnostics Reports First Quarter 2021 Financial Results
May 6, 2021 | finance.yahoo.com

Accelerate Diagnostics to Host Call to Review First Quarter 2021 Results
May 5, 2021 | finance.yahoo.com

Will Accelerate Diagnostics (AXDX) Report Negative Q1 Earnings? What You Should Know
April 29, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AXDX
Previous Symbol
CUSIPN/A
CIK727207
Webacceleratediagnostics.com
Phone520-365-3100
Employees224
Year FoundedN/A

Sales & Book Value

Annual Sales$11.16 million
Price / Sales47.21
Cash FlowN/A
Price / Cash FlowN/A
Book Value($1.06) per share
Price / Book-8.14

Profitability

EPS (Most Recent Fiscal Year)($1.40)
Net Income$-78,210,000.00
Net Margins-715.97%
Return on EquityN/A
Return on Assets-80.10%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares61,044,000
Market Cap$526.81 million
Next Earnings Date8/5/2021 (Estimated)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.65 out of 5 stars

Medical Sector

386th out of 2,100 stocks

Analytical Instruments Industry

9th out of 32 stocks

3.3 Analyst's Opinion

Consensus Rating
Accelerate Diagnostics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $14.50, Accelerate Diagnostics has a forecasted upside of 68.0% from its current price of $8.63.
Amount of Analyst Coverage
Accelerate Diagnostics has only been the subject of 1 research reports in the past 90 days.

2.6 Community Rank

Outperform Votes
Accelerate Diagnostics has received 349 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Accelerate Diagnostics has received 323 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Accelerate Diagnostics has received 51.93% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Accelerate Diagnostics and other stocks. Vote “Outperform” if you believe AXDX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AXDX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Accelerate Diagnostics does not currently pay a dividend.
Dividend Growth
Accelerate Diagnostics does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Accelerate Diagnostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $268,027.00 in company stock.
Percentage Held by Insiders
45.30% of the stock of Accelerate Diagnostics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
40.51% of the stock of Accelerate Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Accelerate Diagnostics are expected to grow in the coming year, from ($1.46) to ($1.25) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Accelerate Diagnostics is -6.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Accelerate Diagnostics is -6.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Accelerate Diagnostics (NASDAQ:AXDX) Frequently Asked Questions

Is Accelerate Diagnostics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Accelerate Diagnostics stock.
View analyst ratings for Accelerate Diagnostics or view top-rated stocks.

What stocks does MarketBeat like better than Accelerate Diagnostics?

Wall Street analysts have given Accelerate Diagnostics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Accelerate Diagnostics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Accelerate Diagnostics' next earnings date?

Accelerate Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Accelerate Diagnostics.

How were Accelerate Diagnostics' earnings last quarter?

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) announced its earnings results on Thursday, May, 6th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.33) by $0.08. The medical research company earned $2.52 million during the quarter, compared to analysts' expectations of $3.55 million.
View Accelerate Diagnostics' earnings history.

How has Accelerate Diagnostics' stock been impacted by COVID-19?

Accelerate Diagnostics' stock was trading at $10.61 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AXDX shares have decreased by 17.3% and is now trading at $8.77.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for AXDX?

3 brokerages have issued 1-year target prices for Accelerate Diagnostics' shares. Their forecasts range from $9.00 to $20.00. On average, they expect Accelerate Diagnostics' stock price to reach $14.50 in the next year. This suggests a possible upside of 65.3% from the stock's current price.
View analysts' price targets for Accelerate Diagnostics or view top-rated stocks among Wall Street analysts.

Who are Accelerate Diagnostics' key executives?

Accelerate Diagnostics' management team includes the following people:

Mr. Jack Phillips, CEO, Pres & Director (Age 55, Pay $619.96k)
Mr. Steve Reichling, CFO, Chief Accounting Officer & Sec. (Age 43, Pay $324.08k)
Mr. Lawrence Mehren, Advisor (Age 55, Pay $293.27k)
Mr. Ron Price, Chief Commercial Officer of Americas (Age 57, Pay $225.23k)
Laura Pierson, Investor Relations Officer
Mr. Michael Bridge, Sr. VP & Gen. Counsel
Ms. Gretchen Strohminger, Sr. VP and Head of HR & Culture
Ms. Constance Bridges, Sr. VP and Head of Regulatory & Quality
Mr. Cherif Bousselham, Sr. VP & Head of Sales - EMEA
Ms. Laura Costa, Sr. VP & Head of Global Customer Support

Who are some of Accelerate Diagnostics' key competitors?

Some companies that are related to Accelerate Diagnostics include Bionano Genomics (BNGO), Singular Genomics Systems (OMIC), Fluidigm (FLDM), Harvard Bioscience (HBIO), Talis Biomedical (TLIS), EyePoint Pharmaceuticals (EYPT), Precipio (PRPO), Astrotech (ASTC), Scientific Industries (SCND), HTG Molecular Diagnostics (HTGM), BioForce Nanosciences (BFNH), Pressure BioSciences (PBIO), Arrayit (ARYC), DiaSys (DYXC) and Orthometrix (OMRX).
View all of AXDX's competitors.

What other stocks do shareholders of Accelerate Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AT&T (T), AbbVie (ABBV) and Micron Technology (MU).

What is Accelerate Diagnostics' stock symbol?

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

Who are Accelerate Diagnostics' major shareholders?

Accelerate Diagnostics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Oracle Investment Management Inc. (6.19%), BlackRock Inc. (3.87%), Birchview Capital LP (3.63%), Chicago Capital LLC (2.60%), Griffin Asset Management Inc. (2.22%) and Cannell Peter B & Co. Inc. (1.79%). Company insiders that own Accelerate Diagnostics stock include Jack Phillips, Jack W Schuler, Romney Humphries, Ron Price and Steven Reichling.
View institutional ownership trends for Accelerate Diagnostics.

Which major investors are selling Accelerate Diagnostics stock?

AXDX stock was sold by a variety of institutional investors in the last quarter, including Griffin Asset Management Inc., Renaissance Technologies LLC, Morgan Stanley, Tudor Investment Corp Et Al, Selkirk Management LLC, GSA Capital Partners LLP, Oracle Investment Management Inc., and D. E. Shaw & Co. Inc.. Company insiders that have sold Accelerate Diagnostics company stock in the last year include Jack Phillips, Romney Humphries, Ron Price, and Steven Reichling.
View insider buying and selling activity for Accelerate Diagnostics or view top insider-selling stocks.

Which major investors are buying Accelerate Diagnostics stock?

AXDX stock was purchased by a variety of institutional investors in the last quarter, including Blair William & Co. IL, Rafferty Asset Management LLC, Graham Capital Management L.P., BlackRock Inc., Geode Capital Management LLC, Millennium Management LLC, Birchview Capital LP, and Algert Global LLC. Company insiders that have bought Accelerate Diagnostics stock in the last two years include Jack W Schuler, and Steven Reichling.
View insider buying and selling activity for Accelerate Diagnostics or or view top insider-buying stocks.

How do I buy shares of Accelerate Diagnostics?

Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Accelerate Diagnostics' stock price today?

One share of AXDX stock can currently be purchased for approximately $8.77.

How much money does Accelerate Diagnostics make?

Accelerate Diagnostics has a market capitalization of $535.36 million and generates $11.16 million in revenue each year. The medical research company earns $-78,210,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis.

How many employees does Accelerate Diagnostics have?

Accelerate Diagnostics employs 224 workers across the globe.

What is Accelerate Diagnostics' official website?

The official website for Accelerate Diagnostics is acceleratediagnostics.com.

Where are Accelerate Diagnostics' headquarters?

Accelerate Diagnostics is headquartered at 3950 South Country Club Suite 470, Tucson AZ, 85714.

How can I contact Accelerate Diagnostics?

Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at 520-365-3100 or via email at [email protected]

This page was last updated on 6/16/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here